» Articles » PMID: 18528930

Etiopathogenesis of Primary Biliary Cirrhosis

Overview
Specialty Gastroenterology
Date 2008 Jun 6
PMID 18528930
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Primary biliary cirrhosis (PBC) is an autoimmune disease of the liver characterized by progressive bile duct destruction eventually leading to cirrhosis and liver failure. The serological hallmark of the disease is the presence of circulating antimitochondrial antibodies (AMA). These reflect the presence of autoreactive T and B cells to the culprit antigens, the E2 subunits of mitochondrial 2-oxo-acid dehydrogenase enzymes, chiefly pyruvate dehydrogenase (PDC-E2). The disease results from a combination of genetic and environmental risk factors. Genetic predisposition is indicated by the higher familial incidence of the disease particularly among siblings and the high concordance rate among monozygotic twins. Environmental triggering events appear crucial to disrupt a pre-existing unstable immune tolerance of genetic origin allowing, after a long latency, the emergence of clinical disease. Initiating mimetopes of the vulnerable epitope of the PDC-E2 autoantigen can be derived from microbes that utilize the PDC enzyme or, alternatively, environmental xenobiotics/chemical compounds that modify the structure of native proteins to make them immunogenic. A further alternative as a source of antigen is PDC-E2 derived from apoptotic cells. In the effector phase the biliary ductular cell, by reason of its proclivity to express the antigen PDC-E2 in the course of apoptosis, undergoes a multilineage immune attack comprised of CD4(+) and CD8(+) T cells and antibody. In this article, we critically review the available evidence on etiopathogenesis of PBC and present interpretations of complex data, new developments and theories, and nominate directions for future research.

Citing Articles

High neutrophil-lymphocyte ratio indicates a worse response to ursodeoxycholic acid in primary biliary cholangitis: a retrospective cohort study.

Zhu H, Zheng M, He H, Lei H, Tai W, Yang J BMC Gastroenterol. 2023; 23(1):400.

PMID: 37978445 PMC: 10657125. DOI: 10.1186/s12876-023-03031-8.


Paeoniflorin mitigates PBC-induced liver fibrosis by repressing NLRP3 formation.

Zhang Y, Zhang S, Luo X, Zhao H, Xiang X Acta Cir Bras. 2022; 36(11):e361106.

PMID: 35195182 PMC: 8860402. DOI: 10.1590/ACB361106.


Partitioned glioma heritability shows subtype-specific enrichment in immune cells.

Ostrom Q, Edelson J, Byun J, Han Y, Kinnersley B, Melin B Neuro Oncol. 2021; 23(8):1304-1314.

PMID: 33743008 PMC: 8328033. DOI: 10.1093/neuonc/noab072.


A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist.

Onofrio F, Hirschfield G, Gulamhusein A Gastroenterol Hepatol (N Y). 2019; 15(3):145-154.

PMID: 31061656 PMC: 6495411.


Primary biliary cholangitis: a comprehensive overview.

Lleo A, Marzorati S, Anaya J, Gershwin M Hepatol Int. 2017; 11(6):485-499.

PMID: 29164395 DOI: 10.1007/s12072-017-9830-1.


References
1.
Shimoda S, Nakamura M, Ishibashi H, Kawano A, Kamihira T, Sakamoto N . Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis. Gastroenterology. 2003; 124(7):1915-25. DOI: 10.1016/s0016-5085(03)00387-1. View

2.
Long S, Quan C, Van de Water J, Nantz M, Kurth M, BARSKY D . Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with primary biliary cirrhosis. J Immunol. 2001; 167(5):2956-63. DOI: 10.4049/jimmunol.167.5.2956. View

3.
Ross C, Katzov H, Carleton B, Hayden M . Pharmacogenomics and its implications for autoimmune disease. J Autoimmun. 2007; 28(2-3):122-8. DOI: 10.1016/j.jaut.2007.02.008. View

4.
Oertelt S, Ridgway W, Ansari A, Coppel R, Gershwin M . Murine models of primary biliary cirrhosis: Comparisons and contrasts. Hepatol Res. 2007; 37 Suppl 3:S365-9. DOI: 10.1111/j.1872-034X.2007.00226.x. View

5.
Van de Water J, Ansari A, Prindiville T, Coppel R, Ricalton N, Kotzin B . Heterogeneity of autoreactive T cell clones specific for the E2 component of the pyruvate dehydrogenase complex in primary biliary cirrhosis. J Exp Med. 1995; 181(2):723-33. PMC: 2191887. DOI: 10.1084/jem.181.2.723. View